NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 108
(Total Views: 62)
Posted On: 09/20/2024 5:09:55 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution for neurodegenerative diseases,” a recent article reads. “Annovis has a unique market position as the only company developing a drug that inhibits multiple neurotoxic proteins for both Alzheimer’s and Parkinson’s, distinguishing it from other industry players. The company’s commitment is evident in its approach to restoring brain function and improving patient outcomes, highlighting its dedication to pioneering effective therapies in this critical field.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution for neurodegenerative diseases,” a recent article reads. “Annovis has a unique market position as the only company developing a drug that inhibits multiple neurotoxic proteins for both Alzheimer’s and Parkinson’s, distinguishing it from other industry players. The company’s commitment is evident in its approach to restoring brain function and improving patient outcomes, highlighting its dedication to pioneering effective therapies in this critical field.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼